Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
silybin + vitamin E + phospholipids
- Development stage
- Phase 3
- Lead developer
- IBI Lorenzini
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A complex formulation that combines silybin (the main component of silymarin, a natural flavonoid) with vitamin E and phospholipids to improve its bioavailability and antioxidant activity. This complex has been studied for its effects on liver conditions, particularly non-alcoholic fatty liver disease (NAFLD) and HCV-related chronic hepatitis. It shows significant improvements in liver steatosis, enzyme levels, insulin resistance, and markers of liver fibrosis.
- Brand names
- RealsilRA
- Other names
- silybin-vitamin E-phospholipid complexsilybin phytosome complexSilPho
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on silybin + vitamin E + phospholipids.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on silybin + vitamin E + phospholipids.